Merck & Co Inc

NYSE: MRK
$102.87
+$1.25 (+1.2%)
Real Time Data Delayed 15 Min.

MRK Articles

General Electric, Intel, Merck, and Disney led the DJIA to a lower close on Thursday.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.
Johnson & Johnson and Merck were the top performers among the Dow 30 stocks Thursday while Goldman Sachs and Wal-Mart were the big laggards.
The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Cisco, United Technologies, Pfizer, and Merck led the DJIA lower Monday.
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be...
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
Credit Suisse comments on Merck ahead of the American Society of Clinical Oncology (ASCO) conference.
Wal-Mart, UnitedHealth, Merck, and Apple led the DJIA to a nice gain on Thursday.
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
General Electric, Merck, Cisco Systems, and UnitedHealth were to worst-performing Dow stocks on Friday.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still be...